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SaBACKGROUND Even a single additional stroke risk factor in patients with atrial ﬁbrillation may confer a risk of stroke.
However, there is no consensus on how best to treat these patients.
OBJECTIVES Our objective was to investigate the risk of stroke and bleeding and the impact of antithrombotic
therapy among low-risk patients, i.e., with 0 or 1 CHA2DS2-VASc (congestive heart failure, hypertension, age
$75 years, diabetes mellitus, stroke/transient ischemic attack, vascular disease, age 65 to 74 years, sex category) score
risk factor.
METHODS The nationwide cohort for this study was established by linking data from the Danish Civil Registration
System, the Danish National Patient Register, and the Danish National Prescription Registry. We studied 39,400 patients
discharged with incident nonvalvular atrial ﬁbrillation with 0 or 1 CHA2DS2-VASc risk factor; 23,572 were not treated,
5,353 were initiated on aspirin, and 10,475 were initiated on warfarin.
RESULTS Stroke event rates for untreated low-risk patients (CHA2DS2-VASc ¼ 0 [male], 1 [female]) were 0.49 per
100 person-years at 1 year and 0.47 per 100 person-years at full follow-up (intention-to-treat). Bleeding event rates
among untreated low-risk patients were 1.08 per 100 person-years at 1 year and 0.97 at full follow-up. The presence of
1 additional stroke risk factor (CHA2DS2-VASc ¼ 1 [male], ¼ 2 [female]) among untreated patients increased the stroke
rate at 1 year to 1.55 per 100 person-years, representing a signiﬁcant 3.01-fold increase. At the 1-year follow-up, bleeding
increased 2.35-fold, and death increased 3.12-fold.
CONCLUSIONS Low-risk patients (CHA2DS2-VASc ¼ 0 [male], 1 [female]) have a truly low risk for stroke and bleeding.
With 1 additional stroke risk factor (CHA2DS2-VASc ¼ 1 [male], ¼ 2 [female]), there was a signiﬁcant increase in event
rates (particularly mortality) if nonanticoagulated. (J Am Coll Cardiol 2015;65:1385–94) © 2015 by the American College
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1386A trial ﬁbrillation (AF) confers a risk ofstrokes, which is associated withhigh mortality and disability. The
risk of stroke is reduced by oral anticoa-
gulation therapy, which, in historical trials
using vitamin K antagonists (VKAs) such
as warfarin, signiﬁcantly reduced stroke/
systemic embolism by 64% and all-cause
mortality by 26% (1). The effect size of VKA
is probably underestimated because many
strokes in VKA-treated patients occurred
while off therapy or during subtherapeutic
anticoagulation. In contrast, aspirin reduces
stroke by a nonsigniﬁcant 19%, with no im-
pact on mortality (1).SEE PAGE 1395Although AF increases stroke risk 5-fold,
this risk is not homogeneous and depends on addi-
tional stroke risk factors (2,3). In addition, the land-
scape for stroke prevention in AF has changed with
the recognition of the need for well-managed VKA
(with average time-in-therapeutic-range >65% to
70%) (4,5) and the recent availability of the non–
vitamin K antagonist oral anticoagulants (NOACs
[previously referred to as new or novel oral antico-
agulants (6)]), which offer relative efﬁcacy, safety,
and convenience compared with the VKAs (7).
Guidelines have evolved to account for these
developments. The 2012 Focused Update of the
European Society of Cardiology (ESC) guidelines
recommend a clinical practice shift, such that the
initial decision step is to identify low-risk patients
(age <65 years and lone AF [irrespective of sex];
i.e., a CHA2DS2-VASc [congestive heart failure,
hypertension, age $75 years, diabetes mellitus,
stroke/transient ischemic attack, vascular disease,
age 65 to 74 years, sex category] score of 0 for male
patients, 1 for female patients) who do not need any
antithrombotic therapy (7). Patients with $1 addi-
tional stroke risk factor can subsequently be offered
stroke prevention with oral anticoagulation. The 2014
National Institute for Health and Care Excellence
(NICE) guidelines recommend a similar approach, and
aspirin is not recommended (8). However, the 2014
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received October 23, 2014; revised manuscript received JanuaryCardiology/Heart Rhythm Society guidelines recom-
mend oral anticoagulation for patients with a
CHA2DS2-VASc score $2 and no therapy for those with
a CHA2DS2-VASc score of 0; for patients with a
CHA2DS2-VASc score of 1, no therapy, aspirin, or oral
anticoagulation is recommended (9).
Given that even a single risk factor in patients with
CHA2DS2-VASc scores of 1 may confer a high risk of
stroke, as evident in a recent analysis (10), our prin-
cipal objective was to investigate the impact
of anticoagulation in patients with CHA2DS2-VASc
scores of 0 to 1, particularly focusing on risk factors
for stroke and bleeding among low-risk patients
(CHA2DS2-VASc ¼ 0 [male], 1 [female]) and those with
1 additional stroke risk factor (CHA2DS2-VASc ¼ 1
[male], ¼ 2 [female]).
METHODS
REGISTRY DATA. The nationwide cohort for this
study was established by linking data from the Danish
Civil Registration System, the Danish National Patient
Register, and the Danish National Prescription Regis-
try by using the unique personal registration number
provided to all Danish citizens. The Danish National
Patient Register has maintained extensive data on
>99% of all hospital admissions in Denmark since 1977.
The data include date of admission and discharge
diagnosis and have been coded according to the In-
ternational Classiﬁcation of Diseases, 10th Revision
(ICD-10), since 1994. The Danish National Prescription
Registry contains date of purchase, package size, and
type of drugs coded according to the international
Anatomical Therapeutic Chemical Classiﬁcation Sys-
tem for all subsidized prescriptions since 1995.
STUDY POPULATION. We identiﬁed all patients with
an incident hospital diagnosis of nonvalvular AF in
the study period (from 1998 to the end of June 2012)
(Figure 1). Patients immigrating within 2 years were
excluded. Nonvalvular AF was deﬁned as the pres-
ence of AF (ICD-10 code I48) and baseline absence of
mitral stenosis or mechanical heart valves (ICD-10
codes I05 or Z952 through Z954). The index date
was deﬁned as 14 days after hospital discharge for
hospitalized patients and 14 days after diagnosis
for ambulatory patients. The study start of 1998che Diagnostics, Boehringer Ingelheim, and Takeda
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ships relevant to the contents of this paper to disclose.
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FIGURE 1 Flow Chart of Study Population Selection Process
23,572
5,353
10,475
39,400
Low risk population:
Untreated:
Initiated aspirin:
Initiated warfarin:
Total:
Incident AF patients between
1998-2012:
215,373
Invalid ID:
Less than 2 years resident:
Prior stroke or more than 1 risk factor:
Valvular surgery or mitral stenosis
Death within 14 days after discharge:
1,723
794
159,265
900
1,219
Excluded:
Initated both aspirin and warfarin:
Experienced aspirin or warfarin user:
Experienced dabigatran user:
Experienced phenprocomoun user:
1,767
9,535
370
400
Excluded due to treatment:
Low risk population:
51,472
Illustrates patient selection for analyses. AF ¼ atrial ﬁbrillation.
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ities on the basis of hospital diagnoses and claimed
prescriptions for a period before 1998. For comorbid-
ities, a prescription within 1 year before the index date
was required to assume that a patient was in treat-
ment. To establish a low-risk patient population, male
patients with CHA2DS2-VASc scores >1 and female
patients with CHA2DS2-VASc scores >2 were excluded.
Patients not treated with warfarin, phenprocoumon,
aspirin, and dabigatran etexilate within 1 year before
the index date were allocated to the not-treated
group. Patients with a prescription of warfarin or
aspirin within 4 months before the index date were
allocated to the treated group. Patients initiated on
NOACs, phenprocoumon, or with additional warfarin
or aspirin prescriptions between 4 months and 1 year
before the index date were excluded. This established
a new-users design, which has been recommended for
evaluating medication effects with an additional
focus on newly diagnosed patients (11).
OUTCOMES AND COMORBIDITY. The outcome of
stroke/thromboembolism was deﬁned as a combined
endpoint of ischemic stroke (ICD-10 codes I63 and
I64) and systemic embolism (ICD-10 code G45).
Bleeding comprised the following events: intracra-
nial hemorrhage (ICD-10 codes I60 and I61); major
bleeding (ICD-10 codes D62, J942, H113, H356, H431,
N02, N95, R04, R31, and R58); gastrointestinal
bleeding (ICD-10 codes K250, K260, K270, K280, and
K290); and traumatic intracranial bleeding (ICD-10
codes S063C, S064, S065, and S066). Both primary
and secondary diagnoses were included. Supple-
mentary analyses regarding the outcomes of stroke/
thromboembolism (primary diagnoses only), ischemic
stroke, and intracranial hemorrhage were performed.
The outcome of all-cause death was extracted from
the Danish Civil Registration System. Diagnoses
and medications to establish comorbidity, as sum-
marized in the CHA2DS2-VASc score and the HAS-
BLED (hypertension, abnormal renal/liver function,
stroke, bleeding history or predisposition, labile in-
ternational normalized ratio, elderly [>65 years],
drugs/alcohol concomitantly) score, are presented in
Online Tables 1 and 2.
STATISTICAL METHODS. The effects of treatment
strategy were analyzed as intention-to-treat (ITT)
and supplemented by a continuous treatment (CT)
analysis. CT was assumed to be interrupted by pre-
scription of an anticoagulant other than the initial
type or if initiating treatment.
Event rates of reported endpoints were calculated
as the number of events per 100 person-years. Person-
time was censored at the ﬁrst occurring event:electrical cardioversion; AF ablation; death; emigra-
tion; end of study (December 31, 2013); or treatment
interruption (CT analysis only). Effect of 1 risk factor on
outcome within treatment group (no treatment,
aspirin initiated, or warfarin initiated) and contrasts
between treatments within risk factor strata (no risk
factors or 1 risk factor) were estimated by using Cox
proportional hazards models. They were reported
as crude effects and adjusted for potential con-
founders (sex; inclusion year [categorical]; abnormal
renal function; abnormal hepatic function; angio-
tensin receptor blockers or angiotensin-converting
enzyme inhibitor, beta-blocker, or nonsteroidal anti-
inﬂammatory drug treatment; previous electrical
cardioversion or ablation).
Sensitivity analyses regarding the choice of index
date were performed by assuming index date at date
of diagnosis and 30 days after hospital discharge
(results not shown). Data were analyzed by using
Stata/MP version 13 (Stata Corporation, College Sta-
tion, Texas). A p value <0.05 was considered statis-
tically signiﬁcant.
TABLE 1 Characteristics of Patients at Baseline and Day 14 After Discharge With Incident AF Diagnosis
No Treatment Aspirin Initiated Warfarin Initiated
AllNo Risk Factors 1 Risk Factor No Risk Factors 1 Risk Factor No Risk Factors 1 Risk Factor
No. of patients 14,115 9,457 2,182 3,171 4,072 6,403 39,400
AF as primary diagnosis 11,499 (81.5) 6,125 (64.8) 1,790 (82.0) 2,277 (71.8) 3,456 (84.9) 5,113 (79.9) 30,260 (76.8)
Female 5,440 (38.5) 4,422 (46.8) 774 (35.5) 1,256 (39.6) 854 (21.0) 2,134 (33.3) 14,880 (37.8)
Age at AF, yrs 52 (42–59) 66 (59–70) 57 (51–61) 65 (59–70) 57 (50–61) 65 (59–70) 59 (51–65)
CHA2DS2-VASc score 0.39  0.49 1.47  0.50 0.35  0.48 1.40  0.49 0.21  0.41 1.33  0.47 0.86  0.72
CHF or LVD 0 333 (3.5) 0 73 (2.3) 0 322 (5.0) 728 (1.8)
Hypertension 0 3,044 (32.2) 0 1,240 (39.1) 0 2,516 (39.3) 6,800 (17.3)
Age >65 yrs 0 5,265 (55.7) 0 1,527 (48.2) 0 3,279 (51.2) 10,071 (25.6)
Diabetes 0 483 (5.1) 0 90 (2.8) 0 182 (2.8) 755 (1.9)
Myocardial infarction 0 201 (2.1) 0 206 (6.5) 0 62 (1.0) 469 (1.2)
Peripheral arterial disease 0 139 (1.5) 0 40 (1.3) 0 44 (0.7) 223 (0.6)
HAS-BLED 0.38  0.60 1.42  0.76 1.13  0.38 2.05  0.53 0.32  0.52 1.31  0.66 0.95  0.85
Bleeding 825 (5.8) 1,100 (11.6) 136 (6.2) 291 (9.2) 179 (4.4) 497 (7.8) 3,028 (7.7)
Abnormal renal function 215 (1.5) 406 (4.3) 15 (0.7) 45 (1.4) 28 (0.7) 94 (1.5) 803 (2.0)
Abnormal hepatic function 85 (0.6) 110 (1.2) 11 (0.5) 7 (0.2) 1 (0.0) 10 (0.2) 224 (0.6)
Clopidogrel 24 (0.2) 53 (0.6) 20 (0.9) 140 (4.4) 7 (0.2) 13 (0.2) 257 (0.7)
ARB or ACE inhibitor 280 (2.0) 1,997 (21.1) 54 (2.5) 832 (26.2) 100 (2.5) 1,866 (29.1) 5,129 (13.0)
Beta-blocker 4,010 (28.4) 3,801 (40.2) 1,454 (66.6) 2,137 (67.4) 2,336 (57.4) 3,995 (62.4) 17,733 (45.0)
NSAID 3,311 (23.5) 2,700 (28.6) 577 (26.4) 913 (28.8) 971 (23.8) 1,710 (26.7) 10,182 (25.8)
Years follow-up, ITT 6.75  4.46 5.81  4.36 5.83  3.96 5.72  3.96 4.79  4.67 5.01  4.42 5.91  4.45
Years follow-up, CT 4.94  4.30 2.92  3.36 4.76  3.78 4.17  3.74 3.47  4.12 3.55  3.89 4.01  4.02
Values are n (%), median (interquartile range), or mean  SD.
ACE ¼ angiotensin-converting enzyme; AF ¼ atrial ﬁbrillation; ARB ¼ angiotensin receptor blocker; CHA2DS2-VASc ¼ congestive heart failure, hypertension, age $75 years, diabetes mellitus, stroke/
transient ischemic attack, vascular disease, age 65 to 74 years, sex category; CHF ¼ congestive heart failure; CT ¼ continuous treatment; HAS-BLED ¼ hypertension, abnormal renal/liver function, stroke,
bleeding history or predisposition, labile international normalized ratio, elderly (>65 years), drugs/alcohol concomitantly; ITT ¼ intention-to-treat; LVD ¼ left ventricular dysfunction; NSAID ¼ nonsteroidal
anti-inﬂammatory drugs.
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Table 1 summarizes the characteristics of the 39,400
patients with CHA2DS2-VASc scores of 0 to 1 included
in the current analysis; 23,572 were not treated after
discharge, 5,353 were initiated on aspirin, and 10,475
were initiated on warfarin. The mean follow-up
duration was 5.9 years. Approximately 50% of pa-
tients with 1 risk factor had age as the only risk factor
(>65 years), and 90% had either age or hypertension
as the risk factor. Anticoagulated patients with no risk
factors were older, with a lower proportion of female
subjects. Use of angiotensin receptor blockers or
angiotensin-converting enzyme inhibitors and beta-
blockers was higher among patients with initiated
treatment as well as among those with 1 risk factor.
Rates of stroke, bleeding, and death in relation to
no treatment, aspirin, or warfarin use among patients
with AF with CHA2DS2-VASc scores of 0 to 1 are shown
in Table 2. Stroke event rates for untreated low-risk
patients with a CHA2DS2-VASc score of 0 (male) or 1
(female) were 0.49 per 100 person-years at 1 year and
0.47 per 100 person-years at full follow-up on the
basis of the ITT analysis. Using a CT approach, cor-
responding ﬁgures were 0.37 and 0.33, respectively.With 1 additional stroke risk factor, event rates at 1
year for stroke were 1.55 and 1.46 per 100 person-
years on ITT and CT. The overall stroke rate among
included untreated patients was 0.90 per 100 person-
years at 1 year. The 1-year follow-up stroke rate for
each calendar year cohort of untreated patients
(Central Illustration) displayed no marked trends in
stroke rate levels from 1998 to 2015.
One-year ischemic stroke rates were 1.39 per 100
person-years among untreated patients and 0.94
among warfarin-treated patients with 1 risk factor
(CT). The stroke rates varied with the different risk
factors, ranging from 1.13 per 100 person-years for
patients with hypertension, 1.40 for heart failure,
1.80 with age 65 to 74 years, and 3.03 for vascular
disease (full details not shown). Restricting the
analysis to primary diagnoses, the 1-year stroke rates
were 0.27 per 100 person-years for low-risk patients
and 1.18 per 100 person-years for patients with
1 additional risk factor (CT) (Online Table 3).
Bleeding event rates among untreated low-risk
patients (CHA2DS2-VASc scores of 0 [male] or 1
[female]) were low (1.08 per 100 person-years at 1 year
and 0.97 at full follow-up with an ITT approach).
For patients who initiated warfarin treatment, the
TABLE 2 Event Rates Per 100 PYs at 1 Year and Full Follow-Up According to Treatment Strategy Initiated at Day 14 After Discharge With Incident AF
1-Year Follow-Up Full Follow-Up
No Treatment Aspirin Initiated Warfarin Initiated No Treatment Aspirin Initiated Warfarin Initiated
Events/PY Rate Events/PY Rate Events/PY Rate Events/PY Rate Events/PY Rate Events/PY Rate
No risk factors
ITT
Stroke 65/13,370 0.49 16/2,048 0.78 27/3,078 0.88 439/9,3572 0.47 88/12,439 0.71 145/18,971 0.76
Ischemic stroke 58/13,372 0.43 16/2,048 0.78 23/3,080 0.75 405/93,683 0.43 84/12,443 0.68 132/18,997 0.69
Bleeding 144/13,329 1.08 31/2,038 1.52 51/3,067 1.66 885/91,568 0.97 157/12,158 1.29 261/18,418 1.42
ICH 20/13,387 0.15 2/2,053 0.10 5/3,093 0.16 81/95,014 0.09 8/12,704 0.06 25/19,466 0.13
Death 519/13,401 3.87 64/2,054 3.12 68/3,093 2.20 1586/95,311 1.66 223/12,731 1.75 364/19,522 1.86
CT
Stroke 44/12,003 0.37 14/1,897 0.74 24/2,799 0.86 230/69,531 0.33 69/10,296 0.67 88/13,990 0.63
Ischemic stroke 41/12,004 0.34 14/1,897 0.74 20/2,800 0.71 206/69563 0.30 67/10,297 0.65 80/13,997 0.57
Bleeding 118/11,958 0.99 27/1,886 1.43 47/2,784 1.69 509/67,962 0.75 113/10,003 1.13 174/13,487 1.29
ICH 15/12,005 0.12 2/1,899 0.11 4/2,807 0.14 38/69,652 0.05 6/10,371 0.06 17/14,126 0.12
Death 464/12,017 3.86 60/1,900 3.16 53/2,807 1.89 1009/69,766 1.45 177/10,381 1.71 207/14,142 1.46
1 risk factor*
ITT
Stroke 133/8,571 1.55 43/2,964 1.45 55/5,172 1.06 653/52,619 1.24 213/17,416 1.22 334/30,874 1.08
Ischemic stroke 129/8,573 1.50 43/2,964 1.45 53/5,173 1.02 620/52,731 1.18 207/17,421 1.19 316/30,917 1.02
Bleeding 233/8,516 2.74 68/2,949 2.31 124/5,130 2.42 1012/51,452 1.97 373/16,903 2.21 685/29,506 2.32
ICH 31/8,611 0.36 6/2,981 0.20 23/5,189 0.44 132/54,674 0.24 41/18,058 0.23 83/31,897 0.26
Death 978/8,630 11.3 169/2,984 5.66 208/5,197 4.00 3,024/54,979 5.50 752/18,140 4.15 1331/32,107 4.15
CT
Stroke 98/6,698 1.46 39/2,617 1.49 46/4,664 0.99 317/27,376 1.16 160/12,993 1.23 212/22,271 0.95
Ischemic stroke 93/6,699 1.39 39/2,617 1.49 44/4,665 0.94 297/27,402 1.08 156/12,996 1.20 201/22,298 0.90
Bleeding 177/6,644 2.66 55/2,601 2.11 112/4,626 2.42 401/26,611 1.51 219/12,572 1.74 466/21,244 2.19
ICH 24/6,707 0.36 5/2,625 0.19 22/4,674 0.47 49/27,509 0.18 22/13,183 0.17 67/22,606 0.30
Death 820/6,720 12.2 158/2,627 6.02 175/4,681 3.74 1606/27,619 5.81 527/13,231 3.98 765/22,730 3.37
Stroke rates restricted to primary diagnoses are given in Online Table w3. *Presence of 1 risk factor of age >65 years, CHF/LVD, hypertension, diabetes, or vascular disease.
ICH ¼ intracranial hemorrhage; PY ¼ person-years; other abbreviations as in Table 1.
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1389corresponding rates were 1.66 and 1.42 (Table 2). With
additional risk factors, there was a corresponding in-
crease in event rates, with rates at 1 year of 2.42 and at
full follow-up of 2.32 for warfarin-treated patients.
Similar trends were seen with a CT approach. One-year
intracranial hemorrhage event rates among patients
with 1 risk factor were w0.4 for untreated patients
and slightly higher for warfarin-treated patients.
Death rates with no risk factors for untreated patients
were w3.9 and were much higher for the group of
older patients in the group with 1 risk factor.
Figure 2 shows the relative impacts on stroke,
bleeding, and death in relation to no treatment,
aspirin, or warfarin use according to the presence of
1 stroke risk factor among patients with AF with
CHA2DS2-VASc scores of 0 to 1, adjusted for potential
confounding (exact numbers from the crude and
adjusted analyses are presented inOnline Table 4). The
presence of 1 stroke risk factor was associated with
increased stroke by 3.01-fold, bleeding by 2.35-fold,
and death by 3.12-fold (ITT) at 1-year follow-up
for patients receiving no treatment. Correspondinghazard ratios (HRs) for aspirin-treated patients
(ITT) were 1.85, 1.62, and 2.09; for warfarin-treated
patients, corresponding HRs were 1.25, 1.27, and 2.04,
respectively. All increases were signiﬁcant, except
for stroke and bleeding among warfarin-treated pa-
tients. HRs in relation to 1 stroke risk factor for stroke,
primary diagnoses, ischemic stroke endpoints, and
intracranial hemorrhage are given in Online Table 4.
COMPARING THE IMPACT OF ANTITHROMBOTIC
TREATMENTS. Figure 3 summarizes HRs comparing
aspirin versus no treatment, warfarin versus no
treatment, and warfarin versus aspirin, adjusted for
potential confounders (exact numbers from the crude
and adjusted analyses are presented in Online
Tables 5 and 6). In patients with no risk factors (i.e.,
low risk with CHA2DS2-VASc ¼ 0 [male], ¼ 1 [female]),
the adjusted analyses, both at 1 year and at full
follow-up, show a neutral or negative association of
treatment on stroke, bleeding, or death.
In patients with 1 risk factor (i.e., CHA2DS2-VASc ¼
1 [male], ¼ 2 [female]), there was a trend for a
reduction in stroke by warfarin at 1 year (HR 0.76) and
CENTRAL ILLUSTRATION AF and 0 or 1 Additional Stroke Risk Factors
(Top) Flow chart for assessment and selection of stroke prevention therapy for
patients with atrial ﬁbrillation (AF). (Bottom) Time trends of 1-year stroke rates per
100 person-years for patients with untreated AF and 0 or 1 stroke risk factors. CHA2DS2-
VASc ¼ congestive heart failure, hypertension, age $75 years, diabetes mellitus, stroke/
transient ischemic attack, vascular disease, age 65 to 74 years, sex category; NOAC ¼
non–vitamin K antagonist oral anticoagulant; VKA ¼ vitamin K antagonist.
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1390neutral for full follow-up (HR: 0.94), but a signiﬁcant
reduction in death (HR: 0.42 and 0.86, respectively).
Warfarin was neutral on bleeding at 1 year (HR: 0.97),
but there was a signiﬁcantly higher risk at full
follow-up (HR: 1.22 with ITT, 1.62; CT) (Figure 3,
Online Tables 5 and 6).
Aspirin did not confer any reduction in stroke
versus no treatment (HR: 1.01) at 1 year and at full
follow-up (HR: 1.09). At full follow-up, a signiﬁcant
increase in bleeding (HR 1.18 with ITT, 1.31 with CT)
was seen for patients with 1 risk factor (Figure 3).
When comparing warfarin versus aspirin, a non-
signiﬁcant reduction in stroke (HR: 0.75) and a
signiﬁcantly lower death rate (HR: 0.68) were seen at
1 year, whereas bleeding rates were slightly increased
(HR: 1.06). The CT analysis slightly increased these
differences. The CT analysis indicated an increase in
bleeding at full follow-up with warfarin versus aspirin
(HR: 1.23).Detailed adjusted analysis of the stroke endpoints
in Online Table 5 shows a nonsigniﬁcant 1-year
reduction in ischemic stroke (HR: 0.74 with ITT,
0.75 with CT), and no signiﬁcant increase in intra-
cranial hemorrhage (HR: 1.41) (Online Table 6),
although rates were low. With CT, bleeding was
signiﬁcantly increased with aspirin and warfarin
compared with no treatment at full follow-up.
DISCUSSION
In this analysis of a large cohort of patients with
CHA2DS2-VASc scores of 0 to 1, we show that those
deﬁned as low-risk (i.e., CHA2DS2-VASc ¼ 0 [male], ¼
1 [female]) have a truly low risk for stroke, bleeding,
and death. In addition, untreated AF patients with
1 additional stroke risk factor (i.e., CHA2DS2-VASc ¼ 1
[male], ¼ 2 [female]) are at increased 1-year stroke
risk by 3.01-fold, bleeding by 2.35-fold, and death by
3.12-fold. Furthermore, in the patients with 1 risk
factor, there were reductions in stroke and death with
warfarin versus no treatment and with warfarin
versus aspirin, but there was no increase in bleeding
with warfarin versus aspirin. Sample size and low
rates among treated groups led to some conﬁdence
intervals crossing neutral, as with stroke.
These data provide support for the approach
advocated in the stroke prevention guidelines from
the ESC and NICE, whereby the ﬁrst decision step is to
identify truly low-risk patients (CHA2DS2-VASc
score ¼ 0 [male], ¼ 1 [female]) who have such low
event rates that no antithrombotic therapy is recom-
mended. Indeed, such patients do not have a positive
net clinical beneﬁt (NCB) (12) from treatment, sug-
gesting that antithrombotic therapy confers no
advantage and, given the negative NCB, a possible
disadvantage is evident. Our “real-world” data are
also consistent with a modeling analysis by Banerjee
et al. (13), in which NOACs had a positive NCB in AF
patients with $1 stroke risk factor. In large “real-
world” cohorts, aspirin did not decrease stroke risk
and demonstrated no positive NCB when balancing
stroke against serious bleeding (14,15).
Subsequent to the initial step of identifying low-
risk patients, effective stroke prevention (i.e., oral
anticoagulation) is recommended for patients with $1
additional stroke risk factor (CHA2DS2-VASc scores $1
[male] and $2 [female]). Our data support this
recommendation, given stroke event rates >1.5 per
100 person-years at 1 year favoring warfarin treat-
ment. Of note, aspirin resulted in a counterintuitive
reduction in intracranial hemorrhage rates, perhaps
explained by patient selection. Oral anticoagulation is
effective stroke prevention, whether delivered as a
FIGURE 2 Plot of Adjusted HR for Outcome in the Presence of 1 Risk Factor of Age >65 Years, Heart Failure (or Left Ventricular Dysfunction), Hypertension,
Diabetes, or Vascular Disease
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normalized ratio control with a VKA (time-in-
therapeutic range >70%), which offers the best efﬁ-
cacy and safety when VKAs are used (4,5). Indeed,
given the availability of NOACs, the threshold for
treatment may be a stroke rate of 0.9% per year (16).
It has previously been shown that stroke rates could
be as high as 8.1% among patients with a single risk
factor (using the older CHADS2 score [congestive heart
failure, hypertension, age$75 years, diabetes mellitus
[1 point for presence of each], and stroke/transient
ischemic attack [2 points] of 1) when substratiﬁed
according to CHA2DS2-VASc score (17). Even among
those with a low-risk CHADS2 score of 0, stroke
rates, when substratiﬁed according to CHA2DS2-VASc
scores, can range between 0.8% and 3.2% per year if
left untreated. Indeed, when balancing stroke reduc-
tion against the potential for serious bleeding, a
positive NCB for anticoagulation in AF patients
with 1 stroke risk factor has been shown (15). The
NICE guidelines clearly recommend that “aspirinmonotherapy should not be offered for stroke pre-
vention in AF patients,” whereas oral anticoagulation
should be offered to those with a CHA2DS2-VASc
score $2 and offered to men with a CHA2DS2-VASc
score of 1. This recommendation, therefore, is in
alignment with the 2012 ESC guidelines (7).
Although the 2014 American Heart Association/
American College of Cardiology/Heart Rhythm Soci-
ety guidelines recommend oral anticoagulation for
a CHA2DS2-VASc score $2, the recommendations for
a CHA2DS2-VASc score of 1 state “no therapy, as-
pirin or anticoagulation” (9). Female patients with
a CHA2DS2-VASc score of 1 (by virtue of their sex)
are low risk (hence, no antithrombotic therapy is
necessary), but male patients with a CHA2DS2-VASc
score of 1 would be left without stroke prevention if
“no therapy or aspirin” were offered and would be at
risk of fatal and disabling strokes. In a recent study of
untreated AF patients with CHA2DS2-VASc scores of 1,
the annual incidence of stroke was 6.6%, with
the greatest risk conferred by hypertension and
FIGURE 3 Plot of Adjusted HR for Outcome According to Treatment Versus No Treatment Within Strata of the Presence of 1 Risk Factor of Age >65 Years,
Heart Failure (or Left Ventricular Dysfunction), Hypertension, Diabetes, or Vascular Disease
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1392age 65 to 74 years (10). Even among patients unsuited
for warfarin treatment, in whom the common practice
previously was to offer aspirin, the oral factor Xa
inhibitor apixaban was superior to aspirin for stroke
prevention, with a similar rate of major bleeding and
intracranial hemorrhage (18). Of note, other guidelines
(19,20), including the previous U.S. guidelines (21),
recommended oral anticoagulation to patients with 1
stroke risk factor (on the basis of the older CHADS2
score [22]), and both CHA2DS2-VASc and CHADS2scores have many stroke risk factors in common. In
essence, some risk factors weighted at 1 in the
CHA2DS2-VASc score have the same score value in the
older CHADS2 score, in which even the older guide-
lines recommend oral anticoagulation. Otherwise,
such patients (evenwith a single stroke risk factor) will
be exposed to unnecessary risk of disabling or even
fatal thromboembolic complications or death (10,23)
that could otherwise have been prevented. Patients
with AF are desperate to avoid strokes, and a recent
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Because
estimates of the absolute risk of thromboembolism vary, it is
controversial whether male patients with nonvalvular AF who
have 1 CHA2DS2-VASc risk factor or women with 2 risk factors
are at high enough risk of stroke to warrant long-term oral
anticoagulant therapy.
COMPETENCY IN PATIENT CARE: For men with AF and a
CHA2DS2-VASc score of 1 or women with a score of 2, the 2012
ESC guidelines recommend anticoagulation, whereas the 2014
American Heart Association/American College of Cardiology/
Heart Rhythm Society guidelines allow the options of oral
anticoagulation, aspirin, or no therapy.
TRANSLATIONAL OUTLOOK: Randomized trials of
antithrombotic therapy would require very large numbers of
patients, but data from inclusive, prospective registries may
inform clinical practice.
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1393survey on patients’ values and preferences showed
that patients were prepared to accept with oral anti-
coagulation 4.4 episodes of major bleeding just to
prevent 1 stroke (24). In randomized trials, oral anti-
coagulation signiﬁcantly reduces stroke and all-cause
mortality, compared with use of control/placebo (1),
and similar trends were seen in the current study for
patients with $1 additional stroke risk factor.
STUDY LIMITATIONS. We acknowledge the limita-
tions of our observational cohort design, as with
similar “real-world” cohort data. In Danish registries,
the positive predictive value of the AF diagnosis is
high (97%) (25), although our hospitalized patients
with AF may have been a higher risk group for stroke
and bleeding, and the applicability to community-
based (and often asymptomatic and “uncompli-
cated”) AF cohorts is less uncertain. Our event rates
probably differ from other published cohorts, given
the dependence on deﬁnitions used for the particular
dataset and endpoints, as well as populations studied
(e.g., community vs. hospitalized), participation in a
health care plan (vs. none), and trial (vs. nontrial)
cohorts, among others. In addition, the type of
AF (paroxysmal, persistent, or permanent) is not
captured in Danish registries. Nonetheless, this study
included patients with AF diagnosed both in-hospital
and at ambulatory visits.
Although patients with AF in the low-risk stratum
have a low rate of hospitalization, this ﬁnding is
neither static nor predictable, and all published data
show that hospitalization risks with AF are real (and
increasing). Of note, the risk score assignment was
made at baseline and was unaffected or not updated
thereafter. Thus, during the ﬁrst year, the CHA2DS2-
VASc score (and its impact on event rates) was accu-
rately estimated, but as time passed (i.e., for the full
follow-up period), it may have become somewhat less
accurate.
Some event rates in the nonanticoagulated group
may be inﬂuenced by use of aspirin bought without a
prescription, although the proportion of over-the-
counter use is small (26), and it would be unlikely
that patients recommended aspirin treatment on a
regular basis would buy it in the pharmacy without
reimbursement. Given the (nonsigniﬁcant) stroke
reduction of 19% compared with control/placebo in
historical trials, aspirin probably has only a small ef-
fect on stroke. The national prescription registry does
not provide information on indications for treatment;
hence, the aspirin-treated group may especially
include patients given aspirin for other indications
and perhaps not as a permanent treatment. This po-
tential misclassiﬁcation could have inﬂuenced the
estimated rates.Unmeasured confounding is inevitable in obser-
vational studies. Even though the Danish registers
provide almost full coverage of history of hospital
diagnoses and prescriptions, relevant information
from general practice that may potentially explain
some effects is still unavailable. Our registry design
also does not provide details regarding drug changes
over time nor of the quality of anticoagulation control
(e.g., time-in-therapeutic range). We recognize that
treatment adherence/discontinuation is an important
consideration for patient management (27), but a
thorough analysis is beyond the scope of this paper,
which addresses the question of whether CHA2DS2-
VASc would be best managed with “nothing, aspirin,
or warfarin” on the basis of “real-world” observa-
tional data.
CONCLUSIONS
Low-risk patients (i.e., CHA2DS2-VASc ¼ 0 [male], ¼ 1
[female]) have a truly low risk for stroke, intracranial
bleeding, and major bleeding. With 1 additional
stroke risk factor (i.e., CHA2DS2-VASc ¼ 1 [male], ¼ 2
[female]), there was a signiﬁcant increase in event
rates, particularly mortality, if nonanticoagulated.
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